舒绍坤研究员，入选“长江学者奖励计划”青年学者项目

美国南佛罗里达大学博士毕业(2010年)，北京大学肿瘤医院研究员，入选教育部“长江学者奖励计划”青年学者项(2021) 。以第一或责任作者在《Nature》、《Molecular Cell》等杂志发表论文。

邮箱：Shaokun_shu@bjmu.edu.cn

主要研究方向、成就

主要从事从事肿瘤转化研究，聚焦在肿瘤新靶点发现，研究肿瘤抗药性，开发联合用药方案等。主要研究成果包括：通过创新性的结合高通量多组学手段和大规模功能基因组筛选平台，首次鉴定了三阴性乳腺癌特异性的重要致癌靶点基因，在三阴性乳腺癌模型上进行靶向药物临床前试验(Nature, 2016)，研究其作用机理，并进一步研究了肿瘤对靶向药物的抗药性机理，找到克服肿瘤抗药性的联合用药方案 (Molecular Cell，2020)，发现靶向药物的生物标记物，启动临床试验。把靶向药物BET抑制剂应用到三阴性乳腺癌治疗，启动了二期临床试验，同时通过启动联合BET抑制剂和CDK4/6抑制剂，BET抑制剂联合PD-L1抗体的临床试验。近年来，共发表SCI收录学术论文10余篇，包括在Nature， Molecular Cell，Nature Cell Biology, Nature Communication等杂志，多项美国专利，启动和参与两项二期临床实验，课题获得两项研究经费资助, 4次国际会议获奖，2次国际会议口头报告。研究成果被新闻媒体广泛报道，包括Nature News & Views，Faculty of 1000和 GEN (Genetic Engineering & Biotechnology News)。

承担课题

1. 北京大学临床医学+X 青年项目 2020-2021

发表的代表性论文(第一#或责任作者*)

Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 May 7. pii: S1097-2765(20)

Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 May 11;11(1):2350.

Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K. Response and resistance to BET bromodomain inhibitors in triple negative breast cancer. Nature. 2016; 529: 413–417.

Shu S, Polyak K. BET Bromodomain Proteins as Cancer Therapeutic Targets. Cold Spring Harbor Symposia on Quantitative Biology. 2016;81:123-129.

Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, Laszewski T, Luoma A, Marusyk A, Wucherpfennig KW, Wagle N, Fan R, Michor F, McAllister SS, Polyak K. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 Jul;21(7):879-888.

Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan HM, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers WR, Jagani Z, Hogarty MD, Roberts C, Brown M, Stegmaier K, Long H, Shivdasani RA, Pellman D, Polyak K. TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Reports. 2018 Oct 30;25(5):1255-1267

Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research. 2016 Nov 15;76(22):6495-6506.